Does sotatercept improve exercise capacity in patients with pulmonary arterial hypertension receiving stable background therapy?
Patients with pulmonary arterial hypertension who were receiving stable background therapy
Sotatercept
Placebo
Improvement in exercise capacity (as assessed by the 6-minute walk test)surrogate
Sotatercept improves exercise capacity in patients with pulmonary arterial hypertension already on stable background therapy.
In patients with pulmonary arterial hypertension who were receiving stable background therapy, sotatercept resulted in a greater improvement in exercise capacity (as assessed by the 6-minute walk test) than placebo. (Funded by Acceleron Pharma, a subsidiary of MSD; STELLAR ClinicalTrials.gov number, NCT04576988.).
“Pooled analyses across trials further suggest that sotatercept may have a meaningful impact on mortality in patients with PAH.”
Building similarity graph...
Analyzing shared references across papers
Loading...
Marius M. Hoeper
David B. Badesch
Hossein Ardeschir Ghofrani
New England Journal of Medicine
Inserm
Heidelberg University
University Hospital Heidelberg
Building similarity graph...
Analyzing shared references across papers
Loading...
Hoeper et al. (Mon,) studied this question.
www.synapsesocial.com/papers/69d5720b75589c71d767e41c — DOI: https://doi.org/10.1056/nejmoa2213558
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: